Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-It depends on how you use the drug. Authors' reply

被引：0
|
作者：
Bokemeyer, Bernd [1 ,2 ,3 ]
Plachta-Danielzik, Sandra [3 ]
机构：
[1] Interdisciplinary Crohn Colitis Ctr Minden, Minden, Germany
[2] Univ Kiel, Dept Med1, UKSH, Kiel, Germany
[3] Competence Network IBD, Kiel, Germany
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2024年 / 59卷 / 01期
关键词：
D O I：
10.1111/apt.17796
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：142 / 143
页数：2
相关论文
共 9 条
  • [1] Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug
    Con, Danny
    Srinivasan, Ashish
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (01) : 140 - 141
  • [2] Comparative Effectiveness of First-Line Infliximab and Vedolizumab in Patients with Early Ulcerative Colitis
    Hemed, A. Rozenfeld
    Cohen, N. A.
    Green, O.
    Hirsch, A.
    Thurm, T.
    Ron, Y.
    Fishman, S.
    Leibovitzh, H.
    Maharshak, N.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1476 - I1477
  • [3] COST-EFFECTIVENESS OF VEDOLIZUMAB, INFLIXIMAB, AND ADALIMUMAB AS FIRST-LINE THERAPY FOR ULCERATIVE COLITIS
    Beilman, Candace L.
    Fedorak, Richard N.
    Halloran, Brendan P.
    GASTROENTEROLOGY, 2018, 154 (06) : S450 - S450
  • [4] Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it! Authors' reply
    Dreesen, Erwin
    Gils, Ann
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (09) : 1029 - 1030
  • [5] Letter: a case supporting the use of rescue infliximab therapy for fulminant ulcerative colitis in pregnancy - authors' reply
    Schulze, H.
    Esters, P.
    Dignass, A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (03) : 326 - 326
  • [6] Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
    Yokomizo, Lauren
    Limketkai, Berkeley
    Park, K. T.
    BMJ OPEN GASTROENTEROLOGY, 2016, 3 (01):
  • [7] Comparative Effectiveness of First-Line Infliximab and Vedolizumab in Patients with Early Ulcerative Colitis (vol 18, p i1486, 2024)
    Hemed, A. Rozenfeld
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (08): : 1357 - 1357
  • [8] Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
    Pouillon, Lieven
    Van Stappen, Johan
    Bossuyt, Peter
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2018, 32-33 : 17 - 25
  • [9] Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study
    Pudipeddi, Aviv
    Ko, Yanna
    Paramsothy, Sudarshan
    Leong, Rupert W.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
1